MarketLens
Sign Up

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

6 months ago
SHARE THIS ON:

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News3 weeks ago

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Edgewise Therapeutics raised ~$1.55B from selling sevasemten to Servier, extending its cash runway into the early 2030s. The deal self-funds late-stage development of EDG-7500, which showed robust Pha...
Stock News2 months ago

Why This Pharmaceutical Stock Jumped Close to 100% This Week

Shares of a pharmaceutical stock surged nearly 100% this week after agreeing to be acquired by a larger sector firm.
Stock News2 months ago

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.

Revolution Medicines, with a $40B market cap and no revenue, could launch its lead cancer drug within a year, potentially establishing new care standards in certain niches.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

Stock News4 hours ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Stock News5 hours ago

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Stock News6 hours ago

Better AI Chip Stock: Broadcom vs. Nvidia

Stock News6 hours ago

Dell Technologies Sees AI Boom Building as $95B Server Backlog Signals Demand